Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
Fecha de publicación: 30 de agosto de 2021
Autores: Heidi Taipale, PhD, Marco Solmi, PhD, Markku Lähteenvuo, PhD, Antti Tanskanen, PhD, Prof Christoph U Correll, PhD, Prof Jari Tiihonen, PhD
Background: Breast cancer is more common in female patients with schizophrenia than in the general population. It is not known whether treatment with prolactin-increasing antipsychotics contributes to increased odds of breast cancer.